Bioventus Inc
$ 8.86
1.26%
26 Feb - close price
- Market Cap 586,044,000 USD
- Current Price $ 8.86
- High / Low $ 8.98 / 8.72
- Stock P/E 54.69
- Book Value 2.48
- EPS 0.16
- Next Earning Report 2026-03-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.06 %
- 52 Week High 11.25
- 52 Week Low 5.81
About
Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.
Analyst Target Price
$14.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-06 | 2025-05-05 | 2025-03-10 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-07 | 2023-08-08 | 2023-05-16 | 2023-03-31 |
| Reported EPS | 0.15 | 0.21 | -0.0399 | 0.15 | 0.06 | 0.19 | 0.07 | 0.07 | 0.05 | 0.14 | -0.26 | -0.06 |
| Estimated EPS | 0.11 | 0.21 | 0.0228 | 0.085 | 0.03 | 0.07 | -0.07 | 0.02 | -0.02 | 0.03 | -0.15 | 0.05 |
| Surprise | 0.04 | 0 | -0.0627 | 0.065 | 0.03 | 0.12 | 0.14 | 0.05 | 0.07 | 0.11 | -0.11 | -0.11 |
| Surprise Percentage | 36.3636% | 0% | -275% | 76.4706% | 100% | 171.4286% | 200% | 250% | 350% | 366.6667% | -73.3333% | -220% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-10 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BVS
2026-02-14 22:27:37
Bioventus has announced strong financial results for the second quarter of 2024, showing significant growth in revenue and profitability, particularly in its Pain Treatments and Surgical Solutions segments. Despite reporting a net loss due to an impairment charge and litigation costs, the company increased its adjusted EBITDA and raised its full-year financial guidance. Key strategic initiatives include the potential divestiture of its Advanced Rehabilitation Business and the FDA clearance of OSTEOAMP Cannula, aiming to enhance shareholder value and focus on core strengths.
2026-02-04 22:58:31
Anderson Financial Strategies LLC has acquired a new stake of 134,720 shares in Bioventus Inc. (NYSE:BVS) during the third quarter, valued at approximately $901,000. This investment represents about 0.16% ownership of Bioventus and constitutes roughly 0.5% of Anderson Financial Strategies LLC's portfolio. Meanwhile, two directors, Guy P. Nohra and Michelle Mcmurry-Heath, recently reduced their holdings in Bioventus through stock sales.
2026-01-11 03:32:56
Institutional investors own 36% of Bioventus Inc. (NASDAQ:BVS), making the stock vulnerable to their trading decisions. The top 5 shareholders collectively own 52% of the company, with Essex Woodlands Management, Juniper Investment Company, and Smith & Nephew plc being the largest. Despite a 13% loss over the past year, a recent US$55m market cap gain might be welcomed by these institutional owners.
2025-12-05 22:09:42
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Bioventus Inc. (NASDAQ: BVS) breached their fiduciary duties to shareholders. The firm encourages current Bioventus stockholders, especially long-term shareholders, to contact them to discuss potential legal rights and options, including seeking corporate governance reforms or financial incentives. Halper Sadeh LLC emphasizes that shareholder involvement can improve company oversight and enhance shareholder value.
2025-11-17 05:12:40
Bioventus Inc. (BVS) has appointed Ajay Dhankhar, PhD, as a Class II director, effective November 14, 2025. This appointment aligns with the Stockholders Agreement, which allows Smith & Nephew affiliates to designate directors. Dr. Dhankhar will not receive compensation for his role.
2025-11-17 05:12:40
Bioventus Inc. has appointed Ajay Dhankhar, PhD, as a Class II director to its board, effective Thursday. Dr. Dhankhar, currently Chief Corporate Development & Strategy Officer at Smith & Nephew plc, will serve until the 2026 annual meeting of stockholders. This appointment aligns with a Stockholders Agreement allowing Smith & Nephew to designate directors, with Dr. Dhankhar being their second designee.
